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Background: To report the results of an audit concerning research gaps in clinical trials that were accepted for
appraisal in authored and published systematic reviews regarding the application of glass-ionomer cements (GIC) in
dental practice
Methods: Information concerning research gaps in trial precision was extracted, following a framework that
included classification of the research gap reasons: ‘imprecision of information (results)’, ‘biased information’,
‘inconsistency or unknown consistency’ and ‘not the right information’, as well as research gap characterization
using PICOS elements: population (P), intervention (I), comparison (C), outcomes (O) and setting (S). Internal trial
validity assessment was based on the understanding that successful control for systematic error cannot be assured
on the basis of inclusion of adequate methods alone, but also requires empirical evidence about whether such
attempt was successful.
Results: A comprehensive and interconnected coverage of GIC-related clinical topics was established. The most
common reasons found for gaps in trial precision were lack of sufficient trials and lack of sufficient large sample
size. Only a few research gaps were ascribed to ‘Lack of information’ caused by focus on mainly surrogate trial
outcomes. According to the chosen assessment criteria, a lack of adequate randomisation, allocation concealment
and blinding/masking in trials covering all reviewed GIC topics was noted (selection- and detection/performance
bias risk). Trial results appear to be less affected by loss-to-follow-up (attrition bias risk).
Conclusion: This audit represents an adjunct of the systematic review articles it has covered. Its results do not
change the systematic review’s conclusions but highlight existing research gaps concerning the precision and
internal validity of reviewed trials in detail. These gaps should be addressed in future GIC-related clinical
research.Introduction
Systematic reviews are defined, according to the Cochrane
collaboration, as scientific literature reviews aimed at
answering clearly formulated questions through use of sys-
tematic and explicit methods for identifying, selecting and
critically appraising relevant research, and for collecting
and analysing data from the literature included in the re-
view [1]. Through this process, systematic reviews provide
a unique opportunity for also identifying gaps in theCorrespondence: neem@global.co.za
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reproduction in any medium, provided the orcurrently available research on a particular topic and pro-
viding recommendations for addressing these. In order for
such objective to become part and parcel of the regular
systematic review process, it has been suggested that the
identification of research gaps should follow a systematic
approach that is based on widely accepted elements and
provides transparent and reproducible results [2].
Robinson et al. (2011) identified the lack of a systematic
process for the development of ‘future research’ sections
in systematic reviews and developed a framework for
determining research gaps [2]. The framework included a
classification of research gap reasons and research gap
characterization, using the PICOS elements: populationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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setting (S). Reasons for research gaps are classified as
‘imprecision of information (results)’, ‘biased information’,
‘inconsistency or unknown consistency’ and ‘not the right
information’. In addition, a worksheet with instructions for
facilitating the use of such framework during or after sys-
tematic reviews was developed [2].
In order to systematically identify potential research
gaps in clinical trials on the topic of glass-ionomer
cements (GIC) in dentistry, an audit of all authored and
previously published GIC-related systematic reviews
[3-10] was conducted on the basis of recommendations
by Robinson et al. (2011) [2]. All systematic reviews were
conducted and published between March 2010 and March
2011 on clinical topics covering the application of conven-
tional (C-GIC) and resin-modified GIC (RM-GIC). Al-
though each contained recommendations for future
research in their discussion section, these were not derived
on the basis of a systematic framework.
Therefore, the purpose of this article is to provide an
addition to authored and previously published GIC-related
systematic reviews by reporting on the results of an audit
concerning identified research gaps in clinical trials cover-
ing the application of glass-ionomer cements in dental
practice.
Materials and method
All authored systematic reviews published on the topic
of glass-ionomer cement (GIC) [3-10] were selected and
reviewed in relation to aspects of the precision and in-
ternal validity of the accepted clinical trials.
Information concerning trial precision was extracted,
following recommendations by Robinson et al. regarding a
framework for identifying research gaps during systematic
reviews [2]. In the context of this audit, the following clas-
sification was adopted for investigating research gaps in
the precision of clinical trials:
(i) Imprecision of results: e.g. confidence intervals
(95% CI) wide enough to suggest both superiority
and inferiority at the same time; no, or too few trials
found; too small sample size of clinical trials
accepted in systematic reviews [2,11,12].
(ii)Inconsistency/unknown consistency of results: e.g.
conflicting directions of effect sizes; magnitude of
differences in effect sizes and significance of such
differences; non-overlapping confidence intervals
(95% CI); unexplained clinical and/or statistical
heterogeneity; lack of sufficient trials (at least two
trials are needed in order to assess consistency)
[2,11].
(iii)Lack of right information: e.g. only surrogate
outcomes investigated; follow-up period too short
[2].PICOS characteristics of research gaps included infor-
mation (if available) on (P): age, gender, ethnicity and
clinical patient characteristics; (I) and (C): specific name
(s) of treatment(s); (O): the measured/indented clinical
outcomes (S): type of clinical setting. All extracted infor-
mation was entered into a modified abstraction work-
sheet. Modifications of the worksheet included:
(i) Exclusion of ‘Bias information’ (assessment for
systematic error/bias risk was undertaken separately
in more depth than per the original
recommendations);
(ii)Inclusion of all gap reasons, instead of only the most
important one (thus addressing one of the identified
weaknesses of the framework) [2];
(iii)Sub-grouping of clinical topics per systematic review
(where appropriate).The internal validity of clinical trials was assessed
through three of the systematic reviews [3,4,7], following
recommendations by Berger [13]. Such assessment of in-
ternal trial validity is based on the understanding that suc-
cessful control for systematic error cannot be assured on
the basis of inclusion of adequate methods alone; i.e. ad-
equate generation of random sequence, allocation conceal-
ment, blinding/masking, as part of the trial methodology.
Such inclusion, and even the adequate reporting of such in-
clusion by following the CONSORT statement [14], merely
indicates an attempt to control adequately against system-
atic error. In addition, empirical evidence is required as
part of the trial report, from which it may be ascertained
that such an attempt was indeed successful. Without such
evidence, internal validity of clinical trials cannot be
assured [13].
This form of assessment was not yet adopted in five
systematic reviews [5,6,8-10]. Thus all accepted clinical
trials of these were re-assessed, using the more recent
criteria (Table 1). All results of the internal validity
assessment were collated with each clinical topic per
systematic review.
Results
Research gaps in the precision of clinical trial results
Extracted information indicative of existing research gaps
concerning the precision of clinical trial results related to
GIC are shown in Table 2. The most common reasons for
gaps are found in the ‘Imprecision of results – A’, followed
by ‘Inconsistency of results – B’. These are due to a general
lack of clinical trials; insufficient sample size in available
trials and wide 95% confidence intervals, as well as to large
differences in effect sizes, unexplained existing he-tero-
geneity of data and the difficulty in judging consistency
from single trials, respectively (Table 3). Only few research
Table 1 Quality assessment criteria of trials
Selection bias
Score Criteria Impact on bias risk
Randomisation and
concealment
A Randomisation: Details of any adequate type of allocation
method that generates random sequences, with the patient
as unit of randomization, are reported.1
Doubts may still exist about whether the trial results are
influenced by selection bias but no indication can be
found in the trial report to support such doubt.
Concealment: Trial provides evidence2 that concealment was
indeed effective and that the random sequence could not
have been observed or predicted throughout the duration
of the trial.
B Randomisation: Details of any adequate type of allocation
method that generates random sequences, with the patient
as unit of randomisation,are reported.1
Despite the implementation of a method considered able
to prevent unmasking of the concealed allocation
sequence through direct observation and prediction,
there are reasons to expect that the concealed allocation
sequence may have been unmasked during the course of
the trial.
Concealment: Trial reports on any adequate method for
preventing direct observation3 and prediction4 of the
allocation sequence and sequence generation rules.
C Randomisation: Details of any adequate type of allocation
method that generates random sequences, with the patient
as unit of randomization, are reported.1
Despite the implementation of a method considered able
to prevent unmasking of the concealed allocation
sequence through direct observation, there are reasons for
expecting that operators could have predicted the
concealed allocation sequence.
Concealment: Trial reports on any adequate method to
prevent direct operator observation of allocation sequence
and sequence generation rules3. However, the allocation
sequence and sequence generation may have been
sufficiently predicted.
D Randomisation: Details of any adequate type of allocation
method that generates random sequences, with the patient
as unit of randomization, are reported.1
Despite the theoretical chance for each patient to be
allocated to either treatment group, operator knowledge
of the allocation sequence may have led to patient
allocation that favoured the outcome of one type of
treatment above the other.
Concealment: The trial report does not include information
on how the allocation of random sequence was concealed.
The allocation could have been directly observed and/or
predicted.
0 Trial does not comply with criteria A – D. No guarantee of equal chance for patients to be allocated
to either treatment group. Thus allocation may have
favoured the outcome of one type of treatment above
the other.
Baseline data for randomised trials
A Baseline data collected before randomisation and reported
for both treatment groups. Data shows no significant
differences between both groups.
Evidence is given that randomisation has led to equal
groups, suggesting little risk of selection bias.
B Baseline data collected before randomisation and reported
for both treatment groups. Data shows significant differences
between both groups but has been appropriately statistically
adjusted.
Differences have been adjusted. Thus the influence of
possible selection bias appears to be reduced.
C Baseline data collected before randomisation and reported
for both treatment groups. Data shows significant differences
between both groups without being statistically adjusted.
Reported differences may be due to ineffective
randomisation, thus indicating risk of selection bias.
0 Trial does not comply with criteria A – C. No evidence is given as to whether randomisation has
indeed led to equal groups with differences beyond
chance. Thus differences may exist, indicating selection
bias.
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Table 1 Quality assessment criteria of trials (Continued)
Detection/Performance bias
Blinding/Masking
Score Criteria Impact on bias risk
A Trial reports on any type of method that is known to prevent
patient AND operator AND evaluator from discerning whether
patients are allocated to the test- or the control group
(Blinding/Masking).
Evidence is given that the trial results may not have been
influenced by detection/performance bias which may have
favored the outcome of one type of treatment above the
other.
Trial reports a process by which the effect of Blinding/Masking
was evaluated, as well as the results of such evaluation.
B Trial reports on any type of method that is known to prevent
patient AND operator AND evaluator from discerning whether
patients are allocated to the test- or the control group
(Blinding/Masking).
Doubts may still exist about whether the trial results are
influenced by detection/performance bias but no
indication can be found from the trial report to support
such doubt. However, no evaluation of the blinding/
masking effect has been included in the trial. Thus no
evidence for lack of bias is given.
Trial report does not give reason for doubt that the patient
allocation to either the test- or the control group has been
unmasked throughout the duration of the trial.
C Trial reports on any type of method that is known to prevent
patient AND operator AND evaluator from discerning whether
patients are allocated to the test- or the control group
(Blinding/Masking).
Despite the implementation of a method considered able
to prevent unmasking, there are reasons to expect that
operators/patients could have discovered the allocation.
Trial report gives reason for doubt that the patient allocation
to either the test- or the control group has been unmasked
throughout the duration of the trial.
0 No process able to blind/mask patients AND operators as to
whether patients were allocated to either the test- or the
control group reported or implemented (It is insufficient to
report that blinding/masking was done without reporting
the details of the process).
Knowledge about the patient allocation may have caused
patients/operator to act in a way that may have favoured
the outcome of one type of treatment above the other,
Attrition bias
Loss – to follow up
Score Criteria Impact on bias risk
A Available case analysis, loss-to-follow-up reported per
treatment group. Subsequent sensitivity analysis does not
indicate a possible risk of bias.
The trial allows extraction of evidence that attrition may
not have favoured the outcome of one type of treatment
above the other.
B Available case analysis, loss-to-follow-up reported per
treatment group. Subsequent sensitivity analysis indicates a
possible risk of bias.
The trial allows assessment of the risk that attrition may
have favoured the outcome of one type of treatment
above the other.
0 Trial does not report number of included participants per
treatment group at baseline or gives any indication that
would allow ascertaining of the loss-to-follow up rate per
treatment group.
The trial carries an unknown risk that attrition may have
favoured the outcome of one type of treatment above the
other.
1 Excluded are types of allocation methods that are considered as inadequate: cluster randomisation, fixed block randomisation with block size 2, minimisation,
alternation, randomisation of teeth, use of date of birth or patient record number, “quasi”-randomisation, split-mouth.
2 E.g. by reporting results of the Berger-Exner Test or any other statistical tests that show that covariates of compared groups were similar at baseline.
3 E.g. by opening of opaque envelope, obtaining allocation from tables, computer generated or from other sources.
4 E.g. central randomisation, sequence allocation by other than operator; excluding varied block randomisation.
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assessment of mainly surrogate, instead of clinical out-
comes.
The result of the PICOS assessment (Table 2) shows that
in total 19 different clinical topics were appraised through
the eight systematic reviews [3-10]. Of these, nine topics
related to interventions (I) using RM-GIC and eight to C-
GIC (of which five were related to ART implementation).
Two topics comprised clinical comparisons (I and C) of
both GIC classes with each other, concerning thepermanent and primary dentition (P) with regard to caries
in restoration margin (O). The clinical work of most
reviewed trials was performed in standard dental clinical
settings (S).
The comparison (C) for seven of the eight C-GIC topics
included amalgam restorations and one resin-based pit
and fissure sealant as controls. The subject population (P)
of the C-GIC topics were patients with permanent (5
topics) and primary (3 topics) dentition. The outcomes (O)
were related to caries on pits and fissures, caries on
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SR= Systematic review, A= Imprecision of results; B= Inconsistency of results; C= Lack of right information; GIC=Glass-ionomer cement; RM-GIC=Resin-modified
GIC; C-GIC=Conventional GIC; ART=Atraumatic restorative treatment (C-GIC based); (F)=Containing fluoride; (NF)=Not containing fluoride; T= Topic;
CaOH=Calcium hydroxide cement.
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Table 3 Details of identified research gaps in clinical topics related to trial precision
Research gap Details
Imprecision of results [A] Too few clinical trials
Caries on restoration margins on permanent teeth: C-GIC tooth restorations vs. Amalgam tooth restorations [4]
Caries on restoration margins on primary teeth: C-GIC tooth restorations vs. Amalgam tooth restorations [4]
Success of restorations in permanent teeth: ART vs. Amalgam tooth restorations (Class II), (Class V) [5]
Success of Class II restorations in primary teeth: ART vs. Amalgam tooth restorations [5]
Caries lesions on adjacent permanent teeth: RM-GIC vs. Composite restorations (F), (NF) [6]
Carious lesions around orthodontic brackets: RM-GIC vs. Composite bonding (NF) [7]
Caries on restoration margins on primary teeth: RM-GIC vs. Composite restorations (F), (NF) [7]
Caries on restoration margins on permanent teeth: RM-GIC vs. Composite restorations (F), (NF) [7]
Caries-free restoration margins on permanent teeth: C-GIC vs. RM-GIC restorations [9]
Pulp response on teeth with deep caries: RM-GIC vs. CaOH cement [10]
Sample size too small
Caries on restoration margins on primary teeth: C-GIC tooth restorations vs. Amalgam tooth restorations [4]
Success of restorations in permanent teeth: ART vs. Amalgam tooth restorations (Class II), (Class V) [5]
Carious lesions around orthodontic brackets: RM-GIC vs. Composite bonding (NF) [7]
Caries on restoration margins on permanent teeth: RM-GIC vs. Composite restorations (NF) [7]
Pulp response on teeth with deep caries: RM-GIC vs. CaOH cement [10]
Confidence intervals (95% CI) wide enough to include superiority and inferiority
Caries-free restoration margins on permanent teeth: C-GIC vs. RM-GIC restorations [9]
Inconsistency of results [B] Contradicting directions of effect sizes/Large differences between effect sizes
Caries on pits and fissures of sealed permanent teeth: C-GIC vs. resin-based sealants [3]
Carious lesions around orthodontic brackets: RM-GIC vs. Composite bonding (NF) [7]
Caries on restoration margins on permanent teeth: RM-GIC vs. Composite restorations (NF) [7]
Unexplained heterogeneity
Caries on pits and fissures of sealed permanent teeth: C-GIC vs. resin-based sealants [3]
Only 1 trial found – no assessment of consistency possible
Success of restorations in permanent teeth: ART vs. Amalgam tooth restorations (Class II) [5]
Caries lesions on adjacent permanent teeth: RM-GIC vs. Composite restorations (F), (NF) [6]
Caries on restoration margins on primary teeth: RM-GIC vs. Composite restorations (F), (NF) [7]
Caries on restoration margins on permanent teeth: RM-GIC vs. Composite restorations (F) [7]
Lack of right information [C] Only/mostly surrogate outcomes accessed
Caries lesions on adjacent permanent teeth: RM-GIC vs. Composite restorations (F), (NF) [7]
Pulp response on teeth with deep caries: RM-GIC vs. CaOH cement [10]
GIC=Glass-ionomer cement; RM-GIC= Resin-modified GIC; C-GIC=Conventional GIC; ART=Atraumatic restorative treatment (C-GIC based); (F)=Containing fluoride;
(NF)=Not containing fluoride; T= Topic; CaOH=Calcium hydroxide cement.
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two and five topics, respectively.
RM-GIC was compared (C) against composite resin
(with and without fluoride), resin-based fissure sealant ma-
terial and calcium hydroxide cement in seven, one and one
topics, respectively. The outcomes (O) were related to car-
ies on pits and fissures (1 topic), caries on restoration mar-
gins (4 topics), caries around orthodontic brackets (1
topic), caries on adjacent teeth (2 topics) and pulp response
(1 topic). The studied population (P) comprised patients
with permanent (6 topics) and primary (3 topics) dentition.
Table 3 provides further information as to the specific
clinical topics affected by the identified research gaps.Gaps were identified in regard to clinical comparisons of
C-GIC and RM-GIC versus amalgam, composite resin
(with or without fluoride) and calcium hydroxide cement
to clinical outcomes, related to caries on restoration
margins as well pits and fissures, restoration success
rates, orthodontic bracket bonding failures and pulp
response in deep cavities.
Research gaps in the internal validity of clinical trial
results
Table 4 presents the results of the assessment of system-
atic error/bias risk affecting the internal validity of clin-
ical trial results. This table shows the number of datasets
Table 4 Assessment of systematic error/bias risk of clinical trials per topic
SR T DS Selection bias risk Detection/Performance Attrition
bias riskBias risk
Randomisation and Baseline data comparison Blinding/ Loss-to-
follow -upAllocation concealment between groups Masking
A B C D 0 A B C 0 A B C 0 A B 0
Mickenautsch and
Yengopal, 2011 [3]
[a] 30 30 9 21 30 18 7 5
Mickenautsch and
Yengopal, 2011 [4]
[a] 12 12 2 10 12 10 2
[b] 5 5 1 4 5 3 2
Mickenautsch et al.,
2010 [5]
[a] 1 1 1 1 1
[b] 12 12 9 3 12 3 9
[c] 6 6 6 6 6
[d] 6 1 5 1 5 6 6
[e] 2 1 1 1 1 2 2
Mickenautsch and
Yengopal, 2010 [6]
[b] 12 12 12 12 12
Yengopal and
Mickenautsch, 2011 [7]
[a] 4 4 4 4 4
[b] 2 2 2 2 1 1
[c] 5 5 5 5 5
[d] 4 4 4 4 4
[e] 9 9 9 9 6 3
Yengopal and
Mickenautsch, 2010 [8]
[1] 19 19 19 19 19
Mickenautsch et al.,
2010 [9]
[a] 8 8 8 8 1 7
[b] 14 14 14 14 14
Mickenautsch et al.,
2010 [10]
[a] 18 18 18 18 18
SR= Systematic review; T= Topic; DS = Total number of datasets per topic.
Adequate = Score A; Inadequate = Scores B, C, 0.
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(Table 1). Only criteria “A” indicate adequacy. According
to the chosen assessment criteria, a complete lack of ad-
equate randomisation, allocation concealment and blind-
ing/masking in all the reviewed GIC topics can be noted.
Trials related to the topics of GIC-based fissure sealants
and GIC (including ART) comparison to amalgam
restorations included limited evidence for equivocal
baseline characteristics between intervention groups.
Trial results for most GIC topics appear to be less
affected by loss-to follow up (attrition bias).Discussion
This is the first attempt to adopt a framework for deter-
mining research gaps in systematic reviews [2] on a
specific subject in dentistry. This attempt is limited to
authored systematic review articles concerning GIC only,
and may thus not reflect the totality of potentially exist-
ing research gaps regarding GIC. However, one of the
challenges reported by the team that developed the
framework was that they were not involved with theconduct of the evidence review and the writing of its
results [2]. In seeking to avoid any negative impact of
such challenge, it was decided that only authored sys-
tematic reviews relevant to GIC should be selected and
other systematic reviews based on a systematic literature
search on the GIC topic would not be included. For that
reason, the present audit should not be considered in a
stand-alone capacity, but as an adjunct and partial up-
date of the systematic review articles [3-10] it has cov-
ered. As the scope of this audit did not affect reported
effect sizes and overall values of established internal val-
idity, its results do not change the systematic reviews’
conclusions. Instead, the audit results give empirical sup-
port to the general recommendations, already made in
the original systematic review reports [3-10], for further
research needs in terms of precision and validity.Identified research gaps in the precision of clinical trial
results
The PICOS framework in Table 2 shows a comprehen-
sive and interconnected coverage of GIC-related clinical
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reviews [3-10]: Topics focused on the two relevant clin-
ical classes of glass-ionomer cement (GIC): conventional
GIC and resin-modified GIC (RM-GIC). Both material
classes are related to each other but also differ in aspects
of clinical indication and biocompatibility. Hence, sys-
tematic review evidence was appraised for both in terms
of anticariogenic effects regarding preventive, i.e. pit and
fissure protection [3,4] and restorative indications [4,6,7].
In addition, evidence for RM-GIC was appraised for its
orthodontic indication [7] and claims of its potential
pulp toxicity were reviewed [10]. Further evidence
regarding comparison of the potential anticariogenic
effects of GIC and RM-GIC [9] was assessed. With the
development of the atraumatic restorative treatment ap-
proach (ART), on a C-GIC basis, current clinical evi-
dence concerning the overall success rate of ART fillings
in comparison to amalgam as prevailing gold standard
was included [5].
The results presented in the modified abstraction
worksheet suggest a general lack of trials on many GIC-
related topics as the main reason for research gaps
(Table 2). The same topics suffer from weak statistical
power due to small sample sizes of available trials and
related to wide confidence intervals that render their
results inconclusive (Table 3).
A particular need for more trials of suitable sample
size has been identified for clinical topics concerning
results that were identified as statistically significant: the
longevity (restoration success rate) of Class II and V
ART restorations in permanent teeth, in comparison to
that of amalgam fillings placed with the use of traditional
high-speed drills. Systematic review results concerning
Class II and V restorations identified a statistically sig-
nificant improvement of longevity favouring ART by 28%
over amalgam after 6.3 years, and by 61% after 2.3 years,
respectively [5]. However, according to the findings in
this audit (Table 2 and 3), the precision of these results
are to be regarded as low and thus future studies are
needed in order confirm or reject the initial results.
In a meta-analysis comparing C-GIC and amalgam
restorations, amalgam restorations were found to have a
65% higher chance than C-GIC restorations of having
caries on restoration margins after 6 years [4]. Although
this difference in effect size was reported to be statisti-
cally significant (p = 0.001), its precision is limited, owing
to the small number of trials (n = 2) included.
Identified research gaps in the internal validity of clinical
trial results
According to the chosen assessment criteria (Table 1), none
of the clinical trials accepted for further appraisal in the
eight systematic reviews [3-10] included adequate random-
isation/allocation concealment or blinding/masking, thussuggesting a high risk of selection and detection/perform-
ance bias (Table 4). Some of the trials from three systematic
reviews [3-5] reported on the lack of statistically significant
differences between selected covariates of the test- and con-
trol groups at baseline. Such lack of significant difference
means a lack of evidence that randomisation was ineffective.
However, this may not provide enough evidence that ran-
domisation was effective either, as other non-measured
and/or unknown covariates may exist that differ signifi-
cantly between groups as a result of potential lack of effect-
ive randomisation. Hence, reasons for doubt remain
regarding this point and risk of selection bias may still be
high.
Bias or systematic error constitutes any factor in the
knowledge acquisition process that systematically diverts its
outcomes away from true values [15]. Systematic error,
therefore, limits the internal validity of acquired knowledge
and thus renders all clinical results included in this audit -
even those for which no research gaps in terms of precision
were identified (Table 2 and 3) - in need for confirmation
by higher quality future trials.
Meta-epidemiological studies have attempted to investi-
gate and quantify the bias risk resulting from lack of ad-
equate randomisation/allocation concealment or blinding/
masking. The empirical evidence of these studies was
appraised by a Cochrane systematic review in regard to
randomisation and allocation concealment [16]. Its con-
clusions affirmed that the effect of not using randomisa-
tion could be as large as, or larger than, the expected
effects of intervention, and therefore recommend the use
of random allocation and adequate allocation conceal-
ment. However, the identified evidence for this conclusion
was identified as weak [16]: larger effect estimates were
found in non-randomised trials than in randomised stud-
ies of the same intervention and measured outcome. This
is in agreement with the suggestion that effect-
overestimation due to bias is likely to be most common
[17]. However, the results originated from only one single
meta-epidemiological study [18] and were based on ana-
lysis of vote counting, with no quantitative estimates of ef-
fect [16]. Other studies that investigated randomised
versus non-randomised trials of different interventions
and/or measured outcomes provided overall only incon-
sistent and conflicting evidence [16]. More studies that
consider the influence of heterogeneity due to differences
in clinical intervention and outcome measures are needed
in order to provide better evidence concerning the impact
of potential bias risk on clinical trial results.
In the absence of strong empirical evidence of bias, e.g.
due to lack of adequate randomisation, arguments for cor-
recting potential bias impact still rely largely on logical
considerations. Berger [13] has added to the debate by pre-
senting the logical consideration that successful control
for bias cannot be assured on a basis of inclusion of
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quence, allocation concealment, blinding/masking) alone.
Such inclusion would only indicate an attempt to control
bias adequately but additionally requires evidence, as part
of the trial report, from which it may be ascertained that
such an attempt was indeed successful. Without such evi-
dence, so it is argued, high internal validity of clinical trials
cannot be assured [13]. Even though the empirical basis
for this argument remains weak, the initial evidence [16]
appears to support its adoption into the methodology of
randomised controlled trials (RCT). Such adoption would
also have the benefit of generating a volume of specific
trials that would be available for future comparison in
meta-epidemiological studies: by comparing the outcome
of RCTs, which have adopted the above considerations
with those that have not. An empirical investigation still
provides the best method for conclusively answering ques-
tions concerning adequate bias control. Against this back-
ground, the following recommendations may be made for
future GIC-related RCTs:
(i) Inclusion into the trial report of a detailed
description of the randomisation process, methods
and restriction, as well as detailed description of the
allocation concealment process;
(ii)Inclusion into the trial methodology of any possible
form of quantitative test that may identify the
presence of selection bias; e.g. test for association of
the trial end point with the probability P{E} that a
certain patient receives a certain treatment (test- or
control intervention), as well as inclusion of such
test results into the trial report;
(iii)Inclusion into the trial report of a detailed
description of any form of blinding/masking attempt;
(iv)Inclusion into the trial methodology of any possible
form of quantitative test that may identify the
presence of detection/performance bias; e.g. appraisal
of the opinions of patients and independent
evaluators as to which type of treatment a patient
may have received, followed by statistical
comparison of such data with the actual allocated
treatment sequence, as well as inclusion of the test
results into the trial report.
Conclusions
This audit identified research gaps in the precision and in-
ternal validity of clinical trials on topics regarding the ap-
plication of glass-ionomer cements. Gaps concerning
precision are mainly manifest in the insufficient trial num-
ber and insufficient sample size. Gaps concerning internal
validity are related to uncertainties of potential bias risk
due to inadequate randomisation, concealment of the ran-
dom allocation, as well as blinding/masking. It is recom-
mended that these research gaps may be addressed byfocussing in future randomised controlled trials on the
identified reasons.
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